Rxsight, Inc., a company specializing in ophthalmic medical devices for customizing vision after cataract surgery, has announced its preliminary financial results for the second quarter of 2025.
The company reported that its preliminary second quarter 2025 revenue is expected to be approximately $33.6 million, representing a 4% decrease compared to the prior year period and an 11% decrease compared to the first quarter of 2025.
The decrease in revenue was attributed to the sale of 27,380 light adjustable lenses (LAL®/LAL+®), which reflects a 1% decrease in procedure volume compared to the first quarter of 2025, and a 13% increase in procedure volume compared to the second quarter of 2024. Additionally, the sale of 40 light delivery devices (LDD™s) experienced a 45% decrease compared to the first quarter of 2025 and a 49% decrease compared to the second quarter of 2024.
As of June 30, 2025, the company’s installed base of light delivery devices stood at 1,084, representing a 34% expansion compared to the installed base at the end of the second quarter of 2024.
In response to the second quarter underperformance, the company has revised its 2025 guidance. The revised full-year 2025 revenue is expected to be in the range of $120.0 million to $130.0 million, down from the previous guidance range of $160.0 million to $175.0 million, representing an implied decrease of 14% to 7% compared to 2024.
Furthermore, the company increased its gross margin percentage, with the revised range now at 72% to 74%, up from the previous range of 71% to 73%. This represents an implied increase of 130 basis points to 330 basis points compared to 2024. The operating expense is expected to be in the range of $145.0 to $155.0 million, representing an implied increase of 7% to 14% compared to 2024.
The company's preliminary cash, cash equivalents, and short-term investments as of June 30, 2025, amounted to $227.5 million, a decrease of approximately $1.8 million compared to $229.3 million as of March 31, 2025.
The complete, unaudited financial results for the second quarter of 2025 are expected to be announced on Thursday, August 7, 2025.
Rxsight, Inc. will host a conference call on Tuesday, July 8, 2025, at 5:00 p.m. Eastern Time to discuss its preliminary second quarter 2025 revenue results and revised full-year guidance. The company also plans to report unaudited financial results for the second quarter of 2025 after the market close on Thursday, August 7, 2025.
This information was retrieved from the company's press release. Today the company's shares have moved 2.9% to a price of $12.79. For the full picture, make sure to review RxSight's 8-K report.
